ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trastuzumab envedotin

Also written as “DP303c”, “DP303c injection” and “DP303c treatment”.

Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Stomach Neoplasms, led by 2 companies.

Drug pageTrastuzumab envedotin: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 4, 20237 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Groupits history only62 open or runningphase 3since Jun 4, 2023Mar 22, 2021none ahead
Shanghai Runshi Pharmaceutical Technology11 open or runningphase 2since Aug 21, 2024Aug 21, 2024none ahead
  • Named in CSPC Pharmaceutical Group’s own pipeline as trastuzumab envedotin, phase 4, as of Aug 20, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Shanghai Runshi Pharmaceutical Technology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 29, 2024Named trastuzumab envedotinINNProposed as its International Nonproprietary Name in WHO's List 130
  2. Aug 21, 2024First study: phase 2 study in Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaFirst studyNCT06577376 · 252 planned

TargetBeta

“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and site-specifically conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent mono…”NCIt, read by Claude

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

The one study Shanghai Runshi Pharmaceutical Technology leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06577376Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma2Not yet recruitingAug 26, 2026252

How it is read

Names in the registry

  • “DP303c”, 5 entries
  • “DP303c injection”, 1 entry
  • “DP303c treatment”, 1 entry
  • “DP303c treatment(second-line of HER2-positive)”, 1 entry
  • “DP303c treatment (third-line of HER2-positive)”, 1 entry

Codes read as this program: DP303C.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.